Allergan PLC's generic version of AstraZeneca PLC's blockbuster statin Crestor (rosuvastatin) is likely to need only a few weeks on the US market to surpass total sales of the PCSK9 inhibitors to date.
Generic Crestor Marks The End Of An Era, Should Quickly Outperform PCSK9s
The launch of generic rosuvastatin offers yet another way to calculate the disappointing performance of the PCSK9 inhibitors.
More from Business
• By
The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.
• By
The company said the main reason for expanding its manufacturing capacity was its growing US commercial portfolio and clinical pipeline.
• By
Enzene Biosciences is likely to front-load capacity at its new US facility amid an onshoring focus, CEO Himanshu Gadgil tells Scrip. Possible US tariff exemption for Indian pharma products, impact of higher steel and aluminum tariffs on US manufacturing and a change in the company’s biosimilars strategy are discussed in this wide-ranging interview
• By
Announcing increased full-year earnings guidance and another dividend increase, Johnson & Johnson’s stock price weakened, outweighed by concerns about the replacement of Stelara revenues and possible drug import tariffs.
More from Scrip
• By
Announcing increased full-year earnings guidance and another dividend increase, Johnson & Johnson’s stock price weakened, outweighed by concerns about the replacement of Stelara revenues and possible drug import tariffs.
• By
Regeneron is disappointed by the knock-back for longer dosing intervals for its high-dose version of Eylea, but its supplemental application for a more commercially important shorter four-week regimen has received a priority review.
• By
A brand new R&D center in Massachusetts and a giant manufacturing site for its future obesity drugs are among the key investments in the US.